1. South Korea Stocks

  2. •

    Distribution services

  3. •

    Medical distributors
Eagle Veterinary Technology Co.Ltd.

Eagle Veterinary Technology Co.Ltd.

KKRX:044960
3,025.00
KRW
+10.00
(+0.33%)
353.11EPS
10.76P/E
46.64BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2,047.89
2,640.19
2,154.54
2,476
3,008.52
2,468.77
2,793.44
3,287.71
3,294.23
3,547.06
3,486.31
3,398.55
3,529.44
3,552.78
Basic EPS, GAAP
88.1
134.01
88.73
191.77
137
85
100
200.31
296.36
215.35
242.44
301.86
321.44
353.11
Free Cash Flow per Basic Share
-501.28
-1,616.92
-234.06
155.19
-151.96
42.59
206.28
410.55
479.08
-60.92
16.46
122.53
317.98
258.38
Dividend per Share
- -
- -
- -
- -
- -
- -
19.92
20
40
50
40
40
60
- -
Book Value per Share
2,163.18
2,611.33
2,650.64
2,751.02
2,823.79
2,814.38
2,894.77
3,074.19
3,326.27
3,499.36
3,693.96
3,958.47
4,229.11
4,267.1
Tangible Book Value per Share
2,153.12
2,603.97
2,632.61
2,735.02
2,796.99
2,792.29
2,876.18
3,053.12
3,302.59
3,475.36
3,671.99
3,939.58
4,212.93
4,251.31
Basic Weighted Avg Shares
8
8
12
12
11
12
12
12
12
12
12
12
12
12
Sales/Revenue/Turnover
16,495
20,263
25,105
28,846
34,156
30,262
34,423
40,357
40,437
43,540
42,794
41,717
43,323
43,610
Operating Margin (%)
6.15
7.91
8.18
3.91
8.01
3.72
5.56
8.73
10.37
8.17
7.77
8.58
10.06
10.23
Depreciation Expense
337
454
1,096
1,682
1,854
1,836
2,143
1,950
1,470
1,244
1,186
1,411
1,405
1,404
Net Income, GAAP
710
1,028
1,034
2,234
1,555
1,042
1,232
2,459
3,638
2,643
2,976
3,705
3,946
4,334
Effective Tax Rate (%)
6.62
10.04
14.89
15.23
14.44
5.69
2.52
16.06
6.13
22.91
15.45
16.03
10.69
11.97
Profit Margin (%)
4.3
5.08
4.12
7.75
4.55
3.44
3.58
6.09
9
6.07
6.95
8.88
9.11
9.94
Working Capital
9,289
10,860
7,192
8,288
7,471
11,580
14,841
16,744
18,388
18,036
16,505
17,997
22,207
22,884
LT Debt
5,604
9,292
5,660
5,399
4,403
3,532
3,751
4,217
3,443
3,685
3,271
2,553
3,453
3,429
Total Equity
17,421
29,111
30,929
31,657
31,913
34,546
35,533
37,735
40,830
42,954
45,343
48,590
51,912
52,378
Return on Invested Capital (%)
4.26
4.49
4.32
2.25
5.39
2.52
4.58
7.09
9.07
6.04
5.89
5.8
7.14
7.14
Return on Capital (%)
4.25
4.19
3.36
5.97
4.33
3.31
3.46
6.02
8.31
5.86
6.28
7.32
7.31
7.94
Return on Common Equity (%)
4.22
4.42
3.44
7.14
4.89
3.14
3.52
6.71
9.26
6.31
6.74
7.89
7.85
8.56

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
3,086
3,079
3,065
LT Borrowings
973
2,067
2,091
LT Finance Leases
1,413
1,385
1,338
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
12
12
12
Market Capitalization
52,598
51,370
46,645

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
28,634
30,802
32,380
Cash, Cash Equivalents & STI
7,580
10,424
11,542
Accounts Receivable, Net
8,314
8,603
8,869
Inventories
11,087
10,865
11,141
Total Current Liabilities
7,942
8,595
9,496
Payables & Accruals
- -
- -
- -
ST Debt
3,086
3,079
3,065
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.34%
6.59%
6.84%
Free Cash Flow
57.43%
116.21%
159.5%
Net Income, GAAP
23.47%
12.84%
6.49%
Sales/Revenue/Turnover
6.04%
1.5%
3.85%
Total Cash Common Dividend
- -
- -
50%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
10,587
10,956
9,884
10,290
41,717
2025
10,728
11,026
10,466
11,103
43,323
2026
11,015
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
118.2
82
15.08
86.63
301.86
2025
86.31
92.96
34.42
107.74
321.44
2026
117.99
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
40
2025
- -
- -
- -
- -
60
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
Full Time Employees
110
Sector
Distribution services
Industry
Medical distributors
Address
Yesan-gun South Korea
IPO Date
Nov 16, 2000
Website
eaglevet.com
Similar Companies
DataMeds AI, Inc. (NASDAQ:MEDS)
Selcuk Ecza Deposu Ticaret ve Sanayi A.S. (BIST:SELEC)
McKesson Corporation (NYSE:MCK)
Ibnsina Pharma (EGX:ISPH)
Cardinal Health, Inc. (NYSE:CAH)
Entero Healthcare Solutions Limited (NSE:ENTERO)
Business
Eagle Veterinary Technology Co., Ltd., commonly known as Eagle Vet, is a South Korea-based animal healthcare company engaged in the development, manufacturing, and distribution of veterinary pharmaceuticals, feed additives, nutritional supplements, and companion animal products. Founded in 1970 and headquartered in Yesan-gun, Chungcheongnam-do, with corporate offices in Seoul, South Korea, the company is listed on the KOSDAQ market (KRX: 044960). Eagle Veterinary Technology operates across three core business divisions: Veterinary Pharmaceuticals, Companion Animal Care, and Contract Manufacturing and International Trading. The company offers a comprehensive portfolio of animal health solutions structured into distinct product and service categories: Veterinary Pharmaceuticals, comprising antibacterial agents, broad-spectrum antibiotics, anthelmintics, antiparasitics, anti-inflammatory and antihistaminic drugs, metabolic stimulants, respiratory therapeutics, and vaccines formulated as sterile injectables, water-soluble powders, oral liquids, and in-feed premixes for livestock, including swine, bovine, and poultry; Nutritional Supplements and Feed Additives, encompassing vitamin and mineral complexes, amino acid formulations, acidifiers, probiotics, and enzyme additives designed to enhance livestock growth performance and disease resistance; Companion Animal Products, marketed under dedicated brand platforms including Haruwell, featuring premium dry and wet pet foods, grain-free formulas, functional treats, freeze-dried and air-dried nutritional products, and specialized dietary supplements; and Contract Manufacturing and Commercial Services, providing contract development and manufacturing organization (CDMO) and contract manufacturing (CMO) capabilities for domestic and multinational animal pharmaceutical enterprises, alongside the import and commercial distribution of veterinary raw materials and specialized healthcare brands. Eagle Veterinary Technology operates advanced manufacturing facilities certified under Korea Veterinary Good Manufacturing Practice (KVGMP) and maintains an automated, sterile liquid injectable plant certified under European Union Good Manufacturing Practice (EU GMP) regulations. The company distributes its products domestically and exports to international markets across Europe, Southeast Asia, the Middle East, Africa, and Oceania. In recent strategic developments, the company has expanded its European and global contract manufacturing partnerships, notably delivering sterile injectable antiparasitic formulations to European pharmaceutical partners such as Orion Corporation, while broadening its EU GMP export footprint into Central and Eastern European markets. Within its companion animal division, the company has accelerated product line extensions under its Haruwell brand, launching specialized geriatric and senior pet nutrition lines such as Good Gravy Senior and expanding distribution agreements for super-premium international pet food brands. Furthermore, the company continues to upgrade its automated sterile processing lines and international regulatory compliance frameworks, receiving formal government commendations from South Korea's Ministry of Agriculture, Food and Rural Affairs for excellence in veterinary pharmaceutical export development and safety standards.